Skip to main contentAI and Advanced
/
ALPA · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
AL
NSE · Equity shares · Biotechnology & Drugs-1.35 · -2.21%
Alpa Laboratories ALPA
NSE:INR 59.77
BSE:INR 58
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ALPA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 61.12
Day rangeINR 55.76 — INR 61.9
52-week rangeINR 46 — INR 105.8
Volume24,990
Market cap140.99
P/E6.46
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)105.81
Net Income (INR Cr)15.01
Rev Growth (5 Year %)1.64
EPS Growth (5 Year %)15.68
P/E Ratio6.46
Book Value88.52
EPS7.13
Price/BV0.68Computed
Research path: Interpret Alpa Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ALPAAlpa Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 242.14 | 222.63 | 182.37 |
| Cash Equivalents | 2.2 | Not available | Not available |
| Long Term Debt | 0 | 0 | 0 |
| Common Stock Total | 21.04 | 21.04 | 21.04 |
| Other Current Assets Total | 12.5 | 0.32 | 0.07 |
| Total Assets | 242.14 | 222.63 | 182.37 |
| Current Portof LT Debt/Capital Leases | 2.51 | 0 | 0.79 |
| Cash | 0.64 | 2.22 | 1.71 |
| Total Equity | 186.28 | 171.43 | 151.91 |
| Long Term Investments | 11.09 | 8.77 | 8.27 |
| Retained Earnings(Accumulated Deficit) | 165.24 | 95.43 | 75.91 |
| Total Common Shares Outstanding | 2.1 | 2.1 | 2.1 |
| Tangible Book Valueper Share Common Eq | 88.52 | 81.45 | 72.17 |
| Total Liabilities | 55.86 | 51.19 | 30.46 |
| Total Debt | 2.51 | 0.03 | 5.25 |
| Short Term Investments | 137.97 | 113.06 | 92.97 |
| Cashand Short Term Investments | 140.81 | 115.29 | 94.68 |
| Total Receivables Net | 44.25 | 58.36 | 51.1 |
| Deferred Income Tax | 3.34 | 4.49 | 2.4 |
| Accounts Receivable-Trade Net | 40.83 | 46.83 | 41.15 |
| Property/Plant/Equipment Total-Net | 20.12 | 20.6 | 11.41 |
| Total Current Liabilities | 52.53 | 46.7 | 28.07 |
| Total Inventory | 13.33 | 18.26 | 14.83 |
| Accounts Payable | 17.79 | 18.69 | 11.78 |
| Other Currentliabilities Total | 32.23 | 26.42 | 9.93 |
| Total Long Term Debt | 0 | 0 | 0 |
| Intangibles Net | 0.04 | 0.05 | 0.06 |
| Total Current Assets | 210.9 | 192.49 | 160.98 |
| Accumulated Depreciation Total | Not available | -30.5 | -28.31 |
| Accrued Expenses | Not available | 1.55 | 1.11 |
| Prepaid Expenses | Not available | 0.26 | 0.31 |
| Additional Paid-In Capital | Not available | 54.96 | 54.96 |
| Property/Plant/Equipment Total-Gross | Not available | 51.1 | 39.72 |
| Notes Payable/Short Term Debt | Not available | 0.03 | 4.46 |
| Other Long Term Assets Total | Not available | 0.72 | 0.52 |
| Note Receivable-Long Term | Not available | 0 | 1.12 |
| Other Liabilities Total | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.55
Price to Sale Ratio1.33
Growth
Debt 5Yr CAGR %67.19
Margins
Operating Margin 12m1.13
Operating Margin 5y Avg4.83
Net Profit Margin 12m14.33
Net Profit Margin 5y14.65
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk52.55
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.85 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,385.25 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,994.45 | 1.69 L | 72.73 | — |
| Cipla | INR 1,408.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.2 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 57.19%
- FII
- 0.35%
- Other
- 42.46%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Price to earnings forward of Alpa Laboratories Limited – NSE:ALPA - TradingViewMarket news · 21 Jul 2026, 12:51 am
Price to earnings forward of Alpa Laboratories Limited – NSE:ALPA TradingView
Enterprise value to revenue forward of Alpa Laboratories Limited – NSE:ALPA - TradingViewMarket news · 17 Jul 2026, 6:29 am
Enterprise value to revenue forward of Alpa Laboratories Limited – NSE:ALPA TradingView
Deccan Polypacks Posts Q1 FY27 Loss of ₹0.06 Crore Amidst Zero Revenue - WhalesbookMarket news · 16 Jul 2026, 4:30 pm
Deccan Polypacks Posts Q1 FY27 Loss of ₹0.06 Crore Amidst Zero Revenue Whalesbook
Alpa Laboratories Ltd accepts resignation of Company Secretary - scanx.tradeMarket news · 8 Jul 2026, 6:05 pm
Alpa Laboratories Ltd accepts resignation of Company Secretary scanx.trade
Compare ALPA LAB with - EquitymasterMarket news · 6 Jul 2026, 11:41 pm
Compare ALPA LAB with Equitymaster
Alpa Laboratories Ltd is Rated Sell - Markets MojoMarket news · 4 Jun 2026, 2:50 am
Alpa Laboratories Ltd is Rated Sell Markets Mojo
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results & A.G.M.
- board MeetingsAudited Results
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Alpa Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Alpa Laboratories Limited is an India-based global pharmaceutical company engaged in manufacturing and selling finished pharmaceutical dosage forms. Its product range includes a variety of ethical, generic, and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. Its human use products include capsules, such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Ciprofloxacin Tablet IP / BP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus, Melovin-P Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ALPA
- BSE Code
- 532878
Questions
Stock FAQ
What is the symbol and ISIN of Alpa Laboratories?
Alpa Laboratories has the symbol ALPA and ISIN - INE385I01010.
What is the current price of Alpa Laboratories?
Alpa Laboratories is currently trading at INR 59.77.
What are the year high and year low of Alpa Laboratories?
Alpa Laboratories has a year high of INR 105.80 and a year low of INR 46.00.
What is the market capitalization of Alpa Laboratories?
Alpa Laboratories has a market capitalization of INR 140.99 crore.
What is the P/E ratio of Alpa Laboratories?
Alpa Laboratories has a P/E ratio of 6.46.
What is the dividend yield of Alpa Laboratories?
Alpa Laboratories has a dividend yield of 0.00%.
How is the financial performance of Alpa Laboratories based on revenue, net income, and EPS?
Alpa Laboratories has revenue of INR 105.81 crore, net income of INR 15.01 crore, and EPS of INR 7.20.
What is the book value of Alpa Laboratories?
Alpa Laboratories has a book value of INR 88.52.
What is the debt-to-equity ratio of Alpa Laboratories?
Alpa Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Alpa Laboratories?
Alpa Laboratories has a price-to-book ratio of 0.68 and a price-to-sales ratio of 1.33.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.